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Abstract
Oxidative stress in the central nervous system mediates the increase in sympathetic tone that precedes the development of
hypertension. We hypothesized that by transforming Angiotensin-II (AngII) into Ang-(1–7), ACE2 might reduce AngII-
mediated oxidative stress in the brain and prevent autonomic dysfunction. To test this hypothesis, a relationship between
ACE2 and oxidative stress was first confirmed in a mouse neuroblastoma cell line (Neuro2A cells) treated with AngII and
infected with Ad-hACE2. ACE2 overexpression resulted in a reduction of reactive oxygen species (ROS) formation. In vivo,
ACE2 knockout (ACE2
2/y) mice and non-transgenic (NT) littermates were infused with AngII (10 days) and infected with Ad-
hACE2 in the paraventricular nucleus (PVN). Baseline blood pressure (BP), AngII and brain ROS levels were not different
between young mice (12 weeks). However, cardiac sympathetic tone, brain NADPH oxidase and SOD activities were
significantly increased in ACE2
2/y. Post infusion, plasma and brain AngII levels were also significantly higher in ACE2
2/y,
although BP was similarly increased in both genotypes. ROS formation in the PVN and RVLM was significantly higher in
ACE2
2/y mice following AngII infusion. Similar phenotypes, i.e. increased oxidative stress, exacerbated dysautonomia and
hypertension, were also observed on baseline in mature ACE2
2/y mice (48 weeks). ACE2 gene therapy to the PVN reduced
AngII-mediated increase in NADPH oxidase activity and normalized cardiac dysautonomia in ACE2
2/y mice. Altogether,
these data indicate that ACE2 gene deletion promotes age-dependent oxidative stress, autonomic dysfunction and
hypertension, while PVN-targeted ACE2 gene therapy decreases ROS formation via NADPH oxidase inhibition and improves
autonomic function. Accordingly, ACE2 could represent a new target for the treatment of hypertension-associated
dysautonomia and oxidative stress.
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Introduction
Oxidative stress is a condition of increased production of
reactive oxygen species (ROS) and/or reduction of scavenging
mechanisms. It has been well established that ROS play an
important role in the development of autonomic dysfunction
preceding cardiovascular diseases, including hypertension [1].
Angiotensin (Ang)-II, one of the major actors of the renin-
angiotensin-system (RAS), is a potent activator of NAD(P)H
oxidase and is involved in the generation of ROS such as
superoxide and hydrogen peroxide [2]. Abundant evidence
suggests that a key mechanism by which AngII influences
autonomic dysfunction is via its ability to produce ROS [2,3]. In
the past several years, new evidence demonstrated the crucial
role of brain ROS in mediating AngII central effects and BP
regulation [4,5,6]. It has been shown that production of ROS in
specific brain regions, including hypothalamus (HT) and rostral
ventrolateral medulla (RVLM), mediates sympatho-excitation,
leading to hypertension [7,8]. AngII-mediated ROS generation
in the brain also results in impaired baroreflex sensitivity [9],
contributing to the increased sympathetic outflow and dysauto-
nomia. Chronic systemic infusion of sub-pressor doses of AngII
increases ROS production in the subfornical organ (SFO) and
leads to the development of hypertension [4], which is reliant on
a Rac1-dependent NAD(P)H oxidase activation [10]. Similarly,
acute pressor response to central AngII has been shown to be
mediated by NAD(P)H oxidase-dependent production of ROS
in hypothalamic cardiovascular regulatory nuclei, including
SFO and paraventricular nucleus (PVN) [5]. Taken together,
these data support the proposal that ROS are important
mediators in RAS-mediated activation of sympathetic tone
leading to dysautonomia.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22682Angiotensin Converting Enzyme 2 (ACE2), an ACE homologue
[11,12], degrades AngII into Ang-(1–7). The presence of ACE2 in
brain regions involved in the central regulation of cardiovascular
function [13], suggests that ACE2 is part of the brain RAS.
Indeed, evidence show that ACE2 interacts with RAS components
in the central nervous system (CNS) [14,15,16]. Overexpression of
ACE2 in the brain decreases blood pressure (BP) and restores
autonomic function in hypertensive animals [16,17] and prevents
the AngII-mediated development of hypertension [14,18]. How-
ever, whether ROS are involved in this process is unknown.
It was reported that ACE2 gene deletion leads to an age-
dependent cardiomyopathy, which is related to increased AngII-
mediated oxidative stress [19]. In addition, ACE2 inhibition
exacerbates AngII-mediated ROS production in kidneys [20],
while ACE2 gene transfer suppresses AngII-induced increase in
NAD(P)H oxidase subunit p22phox expression and lipid perox-
idation in a human endothelial cell line [21]. These data suggest
that ACE2 may benefit cardiovascular function by opposing
AngII-induced oxidative stress in the brain.
In this study, we hypothesized that ACE2 might prevent
oxidative stress in the CNS that could be beneficial to regulate
sympathetic drive and cardiovascular function. To test this
hypothesis, we 1) confirmed the existence of a link between
ACE2 and oxidative stress in vitro, 2) determined the impact of
ACE2 deletion on ROS formation and autonomic function in
vivo, and 3) assessed the potential of brain ACE2 gene therapy in
the prevention of oxidative stress and dysautonomia. Our data
show that ACE2 deletion resulted in age-dependent increases in
oxidative stress, autonomic dysfunction and BP. Moreover, lack of
ACE2 exacerbated AngII-mediated oxidative stress in the CNS.
Finally, ACE2 gene therapy to the PVN prevented AngII-
mediated ROS production in the brain, and restored autonomic
function.
Materials and Methods
Cell Culture
Neuro2A mouse neuroblastoma cells (ATCC Manassas, VA)
were grown in minimum essential medium (MEM; GIBCOH,
Invitrogen, Carlsbad, CA) with 2 mM L-glutamine and Earle’s
balanced salt solution adjusted to contain 1.5 g/L sodium
bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM sodium
pyruvate and 10% fetal bovine serum (FBS; GIBCOH)a t3 7 uC
under a humidified 95% and 5% (v/v) mixture of air and CO2.
Cells were grown onto chamber slides at a density of 1610
5 cells/
chamber for dihydroethidine (DHE) fluorescence measurement, or
10 cm dishes at a density of 10
6 cells/dish for western blot
experiments. After 24 hr, cells were used for the following
experiments. Each set of experiments was performed in triplicate.
Western blot
Cells were treated with either vehicle or AngII (100 nmol/L in PBS)
for 24 hours, washed with PBS, and collected for western blotting.
Cell pellets were incubated in 300 mL lysis buffer (in mmol/L:
HEPES: 10, NaCl: 150, MgCl2: 5, EGTA: 1, 0.02% (w/v) NaN3,
pH 7.4) containing a protease inhibitors cocktail (Sigma, St Louis,
MO). The lysate was centrifuged twice at 4,000 rpm, 4uC, for
20 min and the supernatant transferred to a clean tube. Protein
concentration was measured using a BCA assay kit (Pearce,
Rockford, IL). Cell lysates (30 mg) were mixed with SDS-PAGE
sample buffer (0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol,
10% 2-mercaptoethanol, 0.004% bromophenol blue), heated at
100uC for 5 min and loaded onto a 4–15% SDS–polyacrylamide
gel for electrophoresis. Proteins were transferred to nitrocellulose
membrane at 200 mA for 3 hr by semi-dry blot (Fisher Scientific,
Houston, TX). Membranes were blocked with 5% non-fat milk in
PBST (1.47 mM NaH2PO4, 8.09 mM Na2HPO4, 145 mM NaCl,
0.05% (v/v) Tween-20H, 0.01% (w/v) thimerosal, pH 7.4) for 1 hr
at room temperature and incubated with rabbit anti-mouse ACE2
(Open Biosciences; 1:500), rabbit anti-AT1R (Santa Cruz, sc-
1173; 1:500), or rabbit-anti-AT2R (Santa Cruz, sc-9040; 1:500)
antibodies, at 4uC, overnight. Membranes were washed with
PBST 4 times for 5 min then incubated with goat anti-rabbit IgG-
HRP (Perkin Elmer; 1:5000) for 1 hour at room temperature.
Specific bands were detected by chemiluminescence according to
the manufacturer’s instructions (ECLH, Perkin Elmer) for
15 minutes at room temperature and re-probed with mouse
anti-a-tubulin (Abcam, ab7291; 1:10000) and goat anti-mouse
IgG-HRP. Bands were quantified by laser densitometry (FujiFilm,
ImageReader version 1.2). Bands corresponding to specific
antibodies were normalized to a-tubulin.
Transgenic mice and animal husbandry
Experiments were performed in young adult (12 weeks age) and
mature (48 weeks age) male ACE2 knockout (ACE2
2/y) mice
(C57bl/6J background) [22] and their non-transgenic (NT)
littermates. Animals were fed standard mouse chow and water
ad libitum. All procedures were approved by the LSU Health
Sciences Center Animal Care and Use Committee and are in
agreement with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (IACUC #2703).
Physiological recordings
Baseline BP was measured in ACE2
2/y and NT mice during 3
days using radio-telemetry, as described [16]. Young mice were
then infused subcutaneously with AngII (600 ng/kg/min), or
vehicle (0.9% saline) for 10 days using osmotic pumps (Alzet). BP
was continually recorded during infusion.
Autonomic function was assessed before and after AngII
infusion using a pharmacological method involving ip injection
of propranolol (b-blocker, 4 mg/kg), atropine (muscarinic receptor
blocker, 1 mg/kg) and chlorisondamine (ganglionic blocker,
10 mg/kg). Changes in HR (DHR) and BP (DBP) were calculated
following administration of these blockers [16].
In another set of experiments, young ACE2
2/y mice were
infused subcutaneously with AngII (600 ng/kg/min), or vehicle
(0.9% saline) for 10 days. On the 3
rd day of AngII infusion, mice
were anesthetized with sodium pentobarbital (50 mg/kg, ip) and
placed in a stereotaxic frame for injection with Ad-hACE2-eGFP
or Ad-eGFP. A glass micropipette connected to a pressure injector
(UMP2, WPI) and containing the virus was lowered into the brain
for bilateral PVN injection (4610
6 pfu/200 nl/side) using the
following coordinates (0.3 mm lateral, 0.5 mm caudal, 5.0 mm
ventral). Following injection, mice were returned to their home
cage and cardiovascular parameters recorded continuously.
At the end of AngII infusion, mice were sacrificed and brain
regions harvested for the following assays.
Fluorogenic Monitoring of Superoxide Production
Neuro2A cells were incubated in serum free medium (SFM) in
presence of Ad-hACE2-eGFP or Ad-eGFP control virus (100 MOI)
for 48 hr [14]. On the third day post infection, GFP expression was
observed, using a fluorescence microscope (Olympus, IX81;
Excitation/emission wavelengths: 488/509 nm), as an index of
successful infection and cells treated for 30 minutes with either
vehicle, AngII (100 nmol/L) alone or losartan (1 mmol/L)+AngII.
The AT1R antagonist Losartan was administered 30 min prior
AngII. The oxidant-sensitive fluorogenic probe DHE (2 mmol/L)
Brain ACE2 and Oxidative Stress
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performed in triplicate. Cells were washed thrice in the dark with
PBS and examined on a fluorescence microscope (Olympus U-
TB190, Japan; Excitation/Emission wavelength: 518/605 nm).
Mouse brains were rapidly dissected, frozen in OCT and stored
at 280uC until use. Brains were cryostat-sectioned to 30 mm and
directly mounted onto chilled microscope slides. Sections were
thawed at room temperature, rehydrated with PBS, incubated
with DHE (1 mM in PBS) for 5 min in the dark. After incubation,
sections were washed thrice for 3 min with PBS. Following the
final wash, sections were coversliped and imaged using a
fluorescence microscope (Olympus U-TB190, Japan; Excitation/
Emission wavelengths: 518/605 nm).
DHE fluorescence was quantified using Image J.
AngII measurement
AngII levels in the mouse plasma and brain were measured by
radioimmunoassay (RIA) as previously reported [23,24]. Briefly,
blood and brain samples were harvested following decapitation.
Trunk blood was collected in chilled tubes containing a mixed
inhibitor solution, microfuged at room temperature, then the
plasma was transferred to ice cold methanol (100%). Brain samples
were immersed in cold methanol (100%) and homogenized
immediately upon harvesting. Plasma and brain homogenates
were centrifuged and the supernatants were dried overnight in a
vacuum centrifuge. The dried fraction was resuspended in RIA
buffer and AngII levels quantitated.
ACE2 activity assay
ACE2 activity was measured in the hypothalamus and ventral
lateral medulla (VLM), as previously reported [16].
NADPH oxidase and SOD activity assay
HT and VLM were homogenized in homogenization buffer (in
mmol/L: HEPES: 20, EDTA: 1) containing a protease inhibitors
cocktail (Sigma, St Louis, MO). The lysate was centrifuged twice
at 3,000 rpm, 4uC for 15 min and the supernatant transferred to a
clean tube. Protein concentration was measured using a BCA
assay kit (Pearce, Rockford, IL).
NADPH oxidase activity was measured by a luminescence
assay. Experiments were performed on a microplate luminometer
(1420 Luminescence Counter, Perkin Elmer) at 37uC using 100 mg
protein/well, NADPH 200 mmol/L and lucigenin 10 mmol/L in
200 ml reaction buffer (in mmol/L: HEPES: 20, NaCl: 9.9, KCl:
4.7, MgSO4: 1.2, KH2PO4: 1, CaCl2: 1.9, NaHCO3: 25,
glucose: 11.1, pH 7.4). In some experiments, oxidase activity was
measured in the presence of a flavoprotein inhibitor, diphenyle-
neiodonium (DPI, 10 mmol/L), to confirm that the measured
activity was attributable to NADPH oxidase. A buffer blank (,2%
of the homogenate signal) was subtracted from each reading.
Chemiluminescence readings were obtained at 60 sec intervals for
an overall measuring time of 40 min, a period over which
maximal chemiluminescence was achieved. Luminescence units
(AU) were normalized to protein amount.
SOD activity in brain homogenates was measured with the
SOD Assay kit (Applied Bioanalytical Labs) according to the
manufacturer’s protocol. The absorbance units (AU) were
normalized to protein amount.
Statistical Analysis
Data are expressed as mean 6SEM. Data were analyzed, when
appropriate, by Student’s t test, repeated measures ANOVA or
one-way ANOVA (after Bartlett test of homogeneity of variance)
followed by Tukey-Kramer correction for multiple comparisons
between means. Statistical comparisons were performed using
Prism5 (GraphPad Software, San Diego, CA). Differences were
considered statistically significant at P,0.05.
Results
ACE2 reduces AngII-mediated oxidative stress in
Neuro2A cells
The relationship between ACE2 and AngII-mediated oxidative
stress in neurons was first assessed using an in vitro approach.
Western bloting showed that Neuro2A cells treated with AngII
exhibited a significant reduction in ACE2 expression compared to
vehicle treatment (0.7060.06 vs. 1.060.03, P,0.01; Figure 1A).
This decrease was accompanied by increased AT1R expression
(1.6460.22 vs. 1.060.06, P,0.05; Figure 1B) while the AT2R
level was not affected (1.0160.05 vs. 1.060.06, P.0.05;
Figure 1C).
To determine whether ACE2 could be beneficial in modulating
AngII-mediated ROS formation, cells were infected with Ad-
hACE2 virus and oxidative stress assessed by DHE staining. AngII
treatment significantly increased ROS in Neuro2A cells (31611
vs. 1.060.5 fold, P,0.01 vs. no treatment; Figure 1D,E), while
pre-infection with Ad-ACE2 significantly attenuated the AngII-
induced oxidative stress (10.163.7 fold, P,0.05; Figure 1D,E).
Losartan pre-treatment completely prevented the AngII-mediated
ROS generation (1.160.5 fold, P,0.05 vs. AngII; Figure 1D,E).
Taken together, these data support the beneficial role of ACE2 in
modulating AngII-mediated ROS formation in neurons.
Impaired cardiac sympathetic and vagal tone in ACE2
2/y
mice
To determine the role of ACE2 in vivo, we first investigated the
consequences of ACE2 gene deletion on cardiovascular function.
We measured BP and autonomic function in young adult (12
weeks) ACE2
2/y mice, on baseline and during AngII infusion.
Baseline BP was not different between ACE2
2/y and NT over 3
days recording [mean arterial pressure (MAP): 10061 vs.
10263 mmHg, P.0.05; Figure 2A,B]. AngII infusion (10 days)
similarly increased MAP in both ACE2
2/y and NT mice (12464
vs. 12663 mmHg, P.0.05; Figure 2B). Baseline cardiac sympa-
thetic drive was significantly higher and vagal tone blunted in
ACE2
2/y compared to NT mice (P,0.05; Figure 2C,D). How-
ever, vascular sympathetic drive was not altered in ACE2
2/y
(P.0.05; Figure 2E). AngII infusion exacerbated cardiac dysau-
tonomia in all mice but these modifications were more
pronounced in ACE2
2/y (P,0.05; Figure 2C,D). Vascular
sympathetic drive was similarly increased in both groups.
Altogether these data suggest that young ACE2
2/y mice exhibit
basal cardiac dysautonomia but not hypertension.
ACE2 deletion exacerbates AngII-mediated oxidative
stress in young mice
To investigate whether ACE2 modulates AngII-mediated
oxidative stress in vivo, we measured ROS and AngII levels in
the brain of ACE2
2/y mice. DHE staining showed that ROS
levels were not different in the PVN and RVLM of young
ACE2
2/y on baseline compared to NT (P.0.05; Figure 3A–D).
However, ROS were significantly more elevated in the PVN
(1.4960.12 vs. 1.2560.04, P,0.05; Figure 3A,B), RVLM
(1.5160.09 vs. 1.2460.09, P,0.05; Figure 3C,D) and in other
brain regions (data not shown) of young ACE2
2/y following AngII
infusion. Baseline AngII levels were not different in the plasma
Brain ACE2 and Oxidative Stress
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2/y mice. Baseline blood pressure traces from
young non-transgenic (NT) and ACE2
2/y (KO) mice over 3 days recording show no differences between genotypes (A). Mean arterial pressure (MAP)
was similarly increased in both NT and KO mice during AngII infusion (B). KO mice exhibited enhanced bradycardia to propranolol (C; *P,0.05 vs. NT;
n=8) and reduced tachycardia following atropine (D; *P,0.05 vs. NT; n=8). AngII infusion significantly increased sympathetic drive (C) and reduced
vagal tone (D) in both NT and KO ({P,0.05 vs. baseline, n=8). Autonomic dysfunction remained more pronounced in KO compared to NT following
AngII infusion. (C,D; {P,0.05 vs. NT+AngII). Changes in BP following ganglionic blockade, an index of vascular sympathetic drive, were not different
between NT and KO on baseline or following AngII infusion (E; P.0.05).
doi:10.1371/journal.pone.0022682.g002
Figure 1. Effects of AngII and ACE2 on oxidative stress in Neuro2A cells. Western blots showed that AngII treatment (100 nmol/L, 24 h)
decreased ACE2 (A; 100 KDa, n=6, **P,0.01 vs. vehicle), increased AT1R (43 KDa; B; n=6, *P,0.05 vs. vehicle) without changing AT2R (44 KDa; C;
P.0.05 vs. vehicle) protein expression. Representative DHE staining (D) and quantified data (E), showing that AngII (100 nmol/L, 30 min) significantly
increased ROS production (n=6, **P,0.01 vs. no treatment). Pre-treatment with Ad-ACE2-eGFP reduced AngII-stimulated ROS formation (n=6,
{P,0.05 vs. AngII+Ad-eGFP, *P,0.05 vs. no treatment). Blockade of AT1R with losartan completely prevented AngII-mediated ROS production (n=6,
{P,0.05 vs. AngII+Ad-eGFP).
doi:10.1371/journal.pone.0022682.g001
Brain ACE2 and Oxidative Stress
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(1.360.1 vs. 1.460.2 fmol/mg, P.0.05; Figure 3F) of ACE2
2/y
compared to NT. In NT mice, AngII infusion significantly
increased AngII in the plasma (Figure 3E) but not in the brain
(Figure 4F). However, ACE2
2/y mice exhibited higher AngII
levels than NT in both plasma (42067 vs. 319615 fmol/ml,
P,0.05; Figure 3E) and brain (2.9160.34 vs. 2.0560.17 fmol/
mg, P,0.05; Figure 3F). These data suggest that lack of ACE2
leads to impaired AngII metabolism, thus resulting in exacerbation
of oxidative stress.
Increased BP, dysautonomia and oxidative stress in
mature ACE2
2/y mice
Because previous work suggested that ACE2 gene deletion leads
to age-dependent cardiomyopathy [19], we investigated BP
regulation and oxidative stress in older (48 weeks) mice.
Interestingly, baseline MAP was significantly increased in mature
ACE2
2/y (10862 mmHg, P,0.05; Figure 4A), but not in mature
NT (10262 mmHg; Figure 4A), compared to young mice
(Figure 2B). Moreover, while cardiac dysautonomia was not
further altered by age (Figure 4B,C), vascular sympathetic drive
was enhanced in mature ACE2
2/y, but not in mature NT
(Figure 4D). Likewise, oxidative stress was exacerbated in several
brain regions of mature ACE2
2/y compared to NT mice (P,0.05;
Figure 4E). Together, these data suggest that ACE2 gene deletion
increased the sensitivity to age-dependent oxidative stress and
autonomic dysfunction.
ACE2 gene therapy prevents AngII-mediated oxidative
stress and autonomic dysfunction
Our data indicate that ACE2
2/y mice exhibit age-dependent
increases in oxidative stress and dysautonomia. Because of the
difficulty to work with older animals and since young ACE2
2/y
infused with AngII have a similar phenotype than mature ACE2
2/y
mice, we chose to investigate whether ACE2 gene therapy in the
brain would prevent autonomic dysfunction and oxidative stress in
Figure 3. ROS and AngII levels in young ACE2
2/y mice. Representative DHE staining and quantified data showing no difference in baseline ROS
levels in the PVN (A, B) or RVLM (C, D) between KO and NT mice (P.0.05, n=8). AngII infusion significantly increased ROS production in these regions
in both genotypes (A–D; *P,0.05 vs. baseline, n=8), with higher levels in KO (A–D; {P,0.05 vs. NT+AngII). Baseline AngII levels in both plasma (E)
and brain (F) were not different between mice (P.0.05, n=8). While AngII infusion significantly increased plasma (E) AngII levels in both genotypes,
only KO mice show elevated brain AngII levels (F) (*P,0.05 vs. baseline, n=8). KO mice exhibited higher plasma and central AngII levels following
AngII infusion ({P,0.05, vs. NT+AngII).
doi:10.1371/journal.pone.0022682.g003
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2/y mice infused with AngII. Accordingly, we
bilaterally infected these mice with Ad-ACE2 or Ad-GFP in the
PVN during AngII infusion. Figure 5A shows typical GFP
expression following unilateral targeting of the PVN. Pilot data
showed that PVN bilateral injection significantly increased ACE2
activity in both HT and VLM of ACE2
2/y mice (Figure 5B,C). Ad-
hACE2 injected in the PVN on the 3
rd day of AngII infusion didnot
alter the course of the developing hypertension (Figure 5D).
However, DHE staining shows that AngII-mediated ROS produc-
tion in PVN (0.5960.04 vs. 1.0060.06 AU), RVLM (0.6760.13 vs.
1.0060.06 AU, P,0.05; Figure 6A,B), SFO and NTS (data not
shown) of ACE2
2/y mice was significantly reduced by ACE2
overexpression. In addition, ACE2 gene therapy reversed the
cardiac autonomic dysfunction previously observed in AngII-
infused ACE2
2/y mice (Figure 2C,D). This was illustrated by a
reduction in cardiac sympathetic drive (DHR to propranolol:
273617 vs. 2158619 bpm, P,0.05; Figure 6C) and a trend to
increase vagal tone (DHR to atropine: +9069v s .+67610 bpm,
P=0.08; Figure 6D) in AngII-infused ACE2
2/y mice. Ad-ACE2
treatmentdidnot changethe unalteredvascular sympathetictone in
these mice. These data suggest that reduction of ROS levels in the
PVN and RVLM, following ACE2 overexpression, is associated
with a reversal of the progressing dysautonomia in ACE2
2/y mice.
ACE2 overexpression decreased NAD(P)H oxidase activity
in the brain
To investigate the mechanisms involved in ACE2 deletion-
mediated oxidative stress in the brain, we assessed NADPH
oxidase and superoxide dismutase (SOD) activities in HT and
VLM. In ACE2
2/y, NADPH oxidase activity was significantly
increased in both regions compared to NT mice (HT: 3.0960.44
vs. 1.060.14 AU, VLM: 2.5060.16 vs. 1.060.13 AU, P,0.05;
Figure 7A, B). It remained higher following AngII infusion,
although AngII increased NADPH oxidase in both genotypes
(P,0.05; Figure 7A, B). ACE2 expression in the PVN blunted the
AngII-mediated increase in NADPH oxidase activity in ACE2
2/y
mice (HT: 3.3360.35 vs. 5.3960.9 AU, VLM: 2.2960.38 vs.
3.2260.29 AU, P,0.05; Figure 5A,B) to the level observed in
NT+AngII. SOD activity was significantly higher in both brain
regions in ACE2
2/y compared to NT mice (HT: 1.1660.07 vs.
1.060.03 AU, VLM: 1.3660.12 vs. 1.060.05 AU, P,0.05;
Figure 7C,D) and was not significantly modified by AngII infusion
(Figure 7C,D). Surprisingly, ACE2 overexpression in the PVN of
ACE2
2/y led to a decreased SOD activity in the HT (0.8660.05
vs. 1.2560.1 AU, P,0.05 vs. KO+AngII+Ad-GFP; Figure 7C)
but not in the VLM (Figure 7D). Altogether, these data suggest
that ACE2 gene therapy to the PVN prevents the AngII-mediated
increase in NADPH oxidase activity in the HT and downstream
VLM, while SOD activity was only affected in HT.
Discussion
ACE2 is a carboxypeptidase implicated in the conversion of
AngII into Ang-(1–7) [25]. It has been well established that AngII
stimulates ROS production in both the periphery and CNS;
however, the role of ACE2 in oxidative stress, especially in the
brain, has not been investigated. The present study highlights the
anti-oxidant potential of ACE2 activation in the brain. The main
new findings of this study are that ACE2 deletion, age-dependently
increases ROS levels, autonomic dysfunction and BP, and
exaggerates AngII infusion-induced oxidative stress in brain
regions related to cardiovascular function. ACE2 gene therapy
reduces AngII-mediated ROS production in the PVN and
downstream nuclei associated with inhibition of NADPH oxidase
and restoration of autonomic function.
It is well known that blood borne AngII can reach the brain (e.g.
via the circumventricular organs) and interact with local AT1R to
increase sympathetic drive, ultimately leading to the development of
hypertension [26]. We previously showed that brain ACE2 activity
was inhibited in a chronically hypertensive mouse model with high
AngII levels and that this decrease was mediated by AT1R [16].
Whether the inhibition of ACE2 activity in that model contributes
Figure 4. Increased BP, autonomic dysfunction and oxidative stress in mature ACE2
2/y mice. Baseline MAP was significantly increased in
mature ACE2
2/y compared to age-matched NT mice (A). Increased sympathetic (B) and decreased parasympathetic (C) tones were also observed in
ACE2
2/y mice (*P,0.05 vs. NT). In addition, vascular sympathetic tone in ACE2
2/y mice was significantly elevated compared to NT (D; *P,0.05 vs. NT).
Moreover, oxidative stress was exacerbated in the several brain regions (SFO: subfornical organ, PVN: paraventricular ncleus, NTS: nucleus of the
tractus solitarius, RVLM: rostral ventrolateral medulla and AP: area postrema) of mature ACE2
2/y compared to NT mice (E; *P,0.05 vs. NT).
doi:10.1371/journal.pone.0022682.g004
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that AngII stimulation of AT1R induces superoxide production in
the brain [4,10,27] and reduces ACE2 expression at the periphery
[28,29]. In this study, we first tested the interaction between AngII,
ACE2, AT1R and AT2R and the participation of oxidative stress in
Neuro2A cells. We observed that AngII treatment decreases ACE2
and increased AT1R protein expression. In addition, increase of
ACE2 expression by adenovirus infection (,100-fold) [14] or
blockade of AT1R using losartan reduces the AngII-mediated ROS
formation. These data suggest that AngII mediates oxidative stress
by acting on AT1R. In addition, inhibition of ACE2 and up-
regulation of AT1R could also contribute to the increase in ROS.
Our data also support an ‘‘anti-oxidant’’ effect for ACE2 activation
in neurons. However, ACE2 infection did not completely prevent
the AngII-induced ROS production in cells, suggesting a partial
metabolism of AngII, most likely due to AngII higher affinity for the
AT1R. The ACE2-mediated reduction of ROS formation could
result from AngII cleavage, and/or inhibition of AT1R, as we
previously showed that over-expression of ACE2 in the brain
decreases AT1R expression [14,18]. Moreover, ACE2 modulation
of AngII-mediated oxidative stress could involve the formation of
Ang-(1–7). This is supported by observations that Ang-(1–7) is
increased in response to ACE2 overexpression [18], stimulates both
eNOS and nNOS activities as well as NO release [30,31,32,33],
inhibits NAD(P)H oxidase activity [34] and prevents AngII-
stimulated superoxide production [35].
At first glance, observations that ACE2 promotes anti-oxidant
effects in neurons might seem to diverge from our in vivo study.
Indeed, ACE2 gene deletion did not change ROS levels in young
mice brain and BP in young ACE2
2/y mice remained unaffected,
consistent with unaltered AngII levels in both plasma and brain.
These findings are in line with previous data in similarly
engineered ACE2
2/y mice, showing no alteration of BP [36,37],
although a small genetic background-associated elevation of
baseline BP has also been reported [22]. We speculate that the
young ACE2
2/y mice are in the early phase of autonomic
dysfunction since only cardiac sympathetic and vagal tones are
affected at this age and later extended to vascular sympathetic
tone, leading to high BP. Indeed, ACE2 removal resulted in age-
dependent increase in brain ROS, progressive autonomic
dysfunction and higher BP in ACE2
2/y mice. On the other hand,
ACE2 gene therapy, in AngII-infused mice, prevented increased
Figure 5. ACE2 expression, activity and MAP in ACE2
2/y mice following ACE2 gene therapy to the PVN. Immunohistochemistry (A)
showing green fluorescent protein (eGFP) expression targeted to the PVN, 7 days after unilateral administration of adenovirus. ACE2 activity in HT (B)
and VLM (C) was significantly lower in ACE2
2/y than NT mice (*P,0.01, n=4). Seven days after ACE2 bilateral adenovirus injection to the PVN, ACE2
activity was significantly increased in HT and downstream VLM in KO mice (*P,0.01 vs. NT, n=4). Ad-hACE2 injected in the PVN of ACE2
2/y on the 3
rd
day of AngII infusion did not alter the course of the developing hypertension (D, P.0.05, n=8).
doi:10.1371/journal.pone.0022682.g005
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suggesting that the carboxypeptidase can lessen oxidative stress
and restore autonomic function. Unlike previous reports from our
group and others [14,17], ACE2 gene therapy to the brain did not
alter the course of AngII-mediated hypertension. This is likely due
to the virus being delivered 3 days after the beginning of AngII
infusion. Indeed, it would have taken an additional 3 days for the
adenovirus to express hACE2 [14], making it possible to see local
effects on ROS and autonomic function but more difficult to see a
correction of BP level that is also affected by peripheral factors
such as vasculature and kidney function.
As also shown by Gurley et al. in plasma [22], AngII infusion
resulted in elevated systemic and brain AngII levels in ACE2
2/y,
contributing to the worsening of autonomic dysfunction in these
mice. In addition, increased AngII levels also contributed to a
higher ROS production in ACE2
2/y mice, confirming the pivotal
role of the enzyme in AngII metabolism and prevention of AngII-
mediated oxidative stress. Altogether, these observations suggest
that the lack of ACE2 activity leads to a progressive rise in ROS
levels that might contribute to impaired cardiac sympathetic drive,
vagal tone and ultimately lead to generalized autonomic
dysfunction and high BP.
PVN and RVLM are important brain regions controlling
autonomic function [38], and increased ROS formation in these
nuclei mediates sympathoexcitation [8,39]. The observation that
ACE2 over-expression in the PVN prevents AngII-mediated ROS
production in this region and the downstream RVLM, highlights
the importance of direct connections between these 2 regions [40].
More importantly, the improvement of autonomic function in
ACE2
2/y mice following ACE2 gene therapy in the PVN indicates
the ability of central ACE2 in countering oxidative stress not only
locally but also in distant regions of the brain. One possible
explanation is the ability of ACE2 to be shed from the plasma
membrane and released in the surrounding milieu [14], here the
cerebrospinal fluid, thus increasing enzyme activity far-away from
the delivery site, such as the VLM. This could explain the lower
ACE2 activity levels in the VLM versus HT, following virus
injection. This hypothesis is also consistent with similar changes in
ROS levels in SFO and NTS (data not shown) which may have
contributed to the overall restoration of autonomic function.
NAD(P)H oxidase catalyzes the reduction of molecular oxygen
to form superoxide. It can be activated by AngII, endothelin,
PDGF, TNFa and others [41]. AngII induces ROS formation
mainly by NAD(P)H oxidase activation [3]. Interestingly, the loss
Figure 6. ACE2 gene therapy decreases AngII-mediated oxidative stress and improves autonomic function in ACE2
2/y mice.
Representative DHE stainings and quantified data showing that AngII-mediated superoxide formation in the PVN (A) and RVLM (B) of ACE2
2/y mice
(left: 106, right: 406 magnification) was blunted by Ad-ACE2 infection in the PVN (*P,0.05 vs. Ad-GFP, n=8). ACE2 over-expression in the PVN
improved autonomic function in ACE2
2/y mice, as illustrated by a reduced sympathetic drive (C; *P,0.05 vs. Ad-GFP, n=8) and a trend to increase
vagal tone (D; P.0.05 vs. Ad-GFP, n=8). Ad-ACE2 treatment did not change the unaltered vascular sympathetic tone in these mice (E).
doi:10.1371/journal.pone.0022682.g006
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in the HT and VLM despite any obvious change in brain or
plasma AngII levels, suggesting that additional factors are involved
in ACE2 deletion-mediated activation of NADPH oxidase.
Increased baseline NADPH oxidase activity in young ACE2
2/y
did not result in apparent ROS formation in these regions, while a
general increase in oxidative stress was observed in mature mice.
This suggests that increased NADPH oxidase activity may have
led to a progressive accumulation of ROS in various brain regions
related to the regulation of cardiovascular function which in turn
could contribute to autonomic dysfunction and elevated BP in
ACE2
2/y mice. The increase in NADPH oxidase activity was
associated with parallel elevation of SOD activity, suggesting that
a balance between ROS generation (NADPH oxidase) and
oxidant scavenging (SOD) in HT and VLM could explain the
unaltered baseline ROS levels in the young ACE2
2/y mice. ACE2
removal exaggerated AngII infusion-induced NAD(P)H oxidase
activation, while it was not able to further increase SOD activity,
therefore resulting in an unbalance between production and
scavenging of ROS and leading to augmented ROS levels. ACE2
overexpression in the PVN reduced AngII-dependent NADPH
oxidase activation in the ACE2
2/y mice HT and VLM, suggesting
that the beneficial effects of central ACE2 in modulating oxidative
stress, involve NADPH oxidase inhibition. Surprisingly, this
reduction was accompanied by a decrease in SOD activity in
the HT but not the VLM, supporting the idea that ACE2
overexpression in the PVN may have affected the oxidant
scavenging enzymes in this area. More studies are needed to
clarify this phenomenon.
In addition to ROS, target of rapamycin (TOR) is involved in
aging. It has been shown that activation of TOR pathway
increases protein synthesis, stimulates cell mass growth and inhibits
translation and autophagy, therefore promoting aging [42], while
inhibition of the TOR pathway prolongs life in yeast [43], worm
[44] and flies [45]. It has been reported that AngII activates
mTOR (TOR in mammals) via PI3-kinase signaling in human
coronary smooth muscle cells [46], and ROS can also activate [47]
or be activated by mTOR [48]. Although we did not investigate
mTOR pathway in this study, the role of mTOR cannot be
excluded from our aged ACE2
2/y. Moreover, ROS-mediated
aging could involve activation of various additional pathways such
as SirT1 [49], Ask1-signalosome and p38 MSPK [50]. Further
studies are needed to address whether these pathways are involved
in age-related high blood pressure following ACE2 deletion.
In summary, our data suggest that ACE2 gene deletion age-
dependently promotes oxidative stress, while ACE2 gene therapy
to the PVN decreases ROS formation via NADPH oxidase
inhibition, thus improving autonomic function and preventing the
long term increase in BP.
Limitations of the study
Despite a lack of ACE2, our data failed to show an increase in
plasma and brain AngII levels. While plasma AngII levels have
been reported to be normal or increased in ACE2
2/y mice [51],
the lack of increased brain AngII levels could be related to the
sensitivity of our approach. Indeed, we previously observed that
icv losartan reduces baseline BP in ACE2
2/y mice [52], suggesting
either increased AngII or AT1R levels in the brain. In the present
study, we measured AngII in a brain sample overlapping several
nuclei which may have resulted in the dilution of AngII levels.
Another limitation of the study is our choice to perform ACE2
gene therapy in young ACE2
2/y mice. This choice was motivated
by the difficulty in performing multiple survival surgeries
(telemetry probe, osmotic pump implantations, PVN viral
injection) combined to multiple drug injections (autonomic
function) in older mice. A better approach would have been to
inject the ACE2 virus in young mice and monitor the effects on
autonomic function and oxidative stress in old mice. However, the
limited life (7–10 days) of the ACE2 adenovirus did not permit
such experiments.
Figure 7. ACE2 overexpression in the PVN decreases NADPH oxidase activity in ACE2
2/y mice. NADPH oxidase activity in HT (A) and VLM
(B) was significantly higher in ACE2
2/y mice on baseline (*P,0.05 vs. NT, n=4). This enzyme activity was significantly increased in NT following AngII
infusion (*P,0.05 vs. NT, n=4) and remained more elevated in ACE2
2/y ({P,0.05 vs. NT+AngII). Ad-ACE2 expression in the PVN of ACE2
2/y
significantly decreased NADPH oxidase activity ({P,0.05 vs. KO+AngII+Ad-GFP). Baseline SOD activity was significantly higher in ACE2
2/y mice (C,D;
*P,0.05 vs. NT, n=4). AngII infusion did not change SOD activity in either genotype (P.0.05, n=4). Ad-ACE2 expression in the PVN of ACE2
2/y
decreased SOD activity in HT (C; {P,0.05 vs. KO+AngII+Ad-GFP) without changing its activity in VLM (D; P.0.05, n=4).
doi:10.1371/journal.pone.0022682.g007
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Oxidative stress is involved in many diseases. While several
effective approaches already exist to prevent ROS formation and
end-organ damage, including ACE inhibitors and AngII receptor
blockers, ACE2 offers a possible new option to fight oxidative
damage by targeting the multiple actors involved in ROS
formation. ACE2 gene therapy or drug-mediated increase in
ACE2 activity could promote: 1) AngII degradation, thus reducing
the activation of the ROS formation cascade; 2) AT1R
downregulation, preventing the activation of NAD(P)H oxidase;
and 3) Ang-(1–7) formation, further inhibiting the NAD(P)H
oxidase complex. While AT1R blockers increase AngII levels, they
also provide the opportunity for AT2R to be activated. However,
it is still unclear how these receptors could modulate oxidative
stress. Future studies will need to address the potential for these
mechanisms, as well as the prospect of combined blockade of
AT1R and ACE2 activation.
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